At Immunomedics, Inc. developing collaborations and partnerships is a key part of our strategy to successfully leverage our portfolio of therapeutic products and platform technologies. Our objective is to enter into mutually beneficial relationships to advance the development of our novel immunotherapeutics for the treatment of patients with cancer, autoimmune and other serious diseases, as well as working with partners to discover and develop products utilizing their proprietary targets.
Our collaboration efforts are largely focused around our clinical stage Antibodies and Antibody-Drug Conjugate Programs. Other areas of focus include earlier stage programs or technology partnering opportunities.
Chief Business Officer
300 The American Road
Morris Plains, NJ 07950